II. Epitheliales Ovarialkarzinom (EOC)


Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., Sovak M.A., Yi J., Nycum L.R.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30 (17): 2039–45

Alberts D., Liu Y., Hannigan E.V., O’ Toole R., Williams S.D., Young J.A., Franklin E.W., Clarke-Pearson D.L., Malviya V.K., DuBeshter B., Adelson M.D., Hoskins W.J.: Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer. N Engl J Med 1996; 335: 1950–1955

Allen D.G., Heintz A.P.M., Touw F.W.M.M.: A meta-analysis of residual disease and survival in stage III and IV carcinoma on the ovary. Eur J Gynaecol Oncol 1995; 16: 349–356

Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A.; and the Gynecologic Oncology G.: Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med 2006; 354: 34–43

Beral V., Gaitskell K., Hermon C., Moser K., Reeves G., Peto R. et al., Collaborative Group On Epidemiological Studies Of Ovarian Cancer: Menopausal hormone use and ovarian cancer risk: individual participant metaanalysis of 52 epidemiological studies. Lancet 2015; 385 (9980): 1835–42. doi: 10.1016/S0140-6736 (14)61687-1. Epub 2015 Feb 13

Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–1259

Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., Mannel R.S., Homesley H.D., Fowler J., Greer B.E., Boente M., Birrer M.J., Liang S.X.; Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–83

Coleman R.L., Spirtos N, Enserro D., Herzog T.J., Sabbatini P., Armstrong D.K., Kim B., Fujiwara K., Walker J.A., Flynn P.J., Alvarez Secord A., Cohn D.E., Brady M.F., Mannel R.S.: A phase III randomized trial of secondary surgical cytoreduction followed by platinum-based chemotherapy with or without bevacizumab in platinum-sensitive recurrent ovarian cancer: A NRG Oncology/Gynecologic Oncology Group Study. Proc ASCO 2018; Abstr. 5501

Crum C.P., Drapkin R., Miron A., Ince T.A., Muto M., Kindelberger D.W., Lee Y.: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3–9

du Bois A., Harter P.: The role of surgery in advanced and recurrent ovarian cancer. Ann Oncol 2006; 17 (Suppl. 10): x235

du Bois A., Vergote I., Ferron G., Reuss A., Meier W., Greggi S., Jensen P., Selle F., Guyon F., Pomel C., Lecuru F., Zang R., Avall-Lunqvist E., Kim J.W., Ponce J., Raspagliesi F., Ghaem-Maghami S., Reinthaller A., Harter P., Sehouli J.: Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: the interim analysis of AGO DESKTOP III / ENGOT ov20. Proc ASCO 2017; Abstr. 5501

Ferlay J., Soerjomataram I., Ervik M. et al.: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr

Fujita M., Enomoto T., Murata Y.: Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003; 202: 97

Griffiths C.T., Parker L.M., Lee S., Finkler N.J.: The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term-results. Int J Gynecol Cancer 2002; 12: 323

Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., Mahner S., Vergote I., Reinthaller A., Burges A., Hanker L., Pölcher M., Kurzeder C., Canzler U., Petry K.U., Obermair A., Petru E., Schmalfeldt B., Lorusso D., du Bois A.: Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21 (2): 289

Havrilesky L.J., Whitehead C.M., Rubatt J.M., Cheek R.L., Groelke J., He Q., Malinowski D.P., Fischer T.J., Berchuck A.: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008; 110 (3): 374

Jaaback K., Johnson N., Lawrie T.A.: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2016; 1: CD005340. doi: 10.1002/14651858.CD005340

Jacob F., Meier M., Caduff R. et al.: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011; 121: 487

Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG 1990; 97: 922

Jacobs I.J., Menon U., Ryan A., Gentry-Maharaj A., Burnell M., Kalsi J.K., Amso N.N., Apostolidou S., Benjamin E., Cruickshank D., Crump D.N., Davies S.K., Dawnay A., Dobbs S., Fletcher G., Ford J., Godfrey K., Gunu R., Habib M., Hallett R., Herod J., Jenkins H., Karpinskyj C., Leeson S., Lewis S.J., Liston W.R., Lopes A., Mould T., Murdoch J., Oram D., Rabideau D.J., Reynolds K., Scott I., Seif M.W., Sharma A., Singh N., Taylor J., Warburton F., Widschwendter M., Williamson K., Woolas R., Fallowfield L., McGuire A.J., Campbell S., Parmar M., Skates S.J.: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2015. pii: S0140- 6736 (15)01224-6. doi: 10.1016/S0140–6736 (15)01224

Kaijser J., Sayasneh A., Van Hoorde K., Ghaem-Maghami S., Bourne T., Timmerman D., Van Calster B.: Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Hum Reprod Update 2014; 20 (3): 449

Kauff N.D., Domchek S.M., Friebel T.M., Robson M.E., Lee J., Garber J.E., Isaacs C., Evans D.G., Lynch H., Eeles R.A., Neuhausen S.L., Daly M.B., Matloff E., Blum J.L., Sabbatini P., Barakat R.R., Hudis C., Norton L., Offit K., Rebbeck T.R.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26: 1331

Kehoe S., Hook J., Nankivell M., Jayson G.C., Kitchener H., Lopes T., Luesley D., Perren T., Bannoo S., Mascarenhas M., Dobbs S., Essapen S., Twigg J., Herod J., McCluggage G., Parmar M., Swart A.M.: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249

Leen S.L., Singh N.: Pathology of primary and metastatic mucinous ovarian neoplasms. J Clin Pathol 2012; 65 (7): 591–5

Lim M.C., Chang S.J., Yoo H.J., Nam H.B., Bristow R.E., Park S.Y.: Hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian or tubal cancer: a multicenter randomized controlled trial. ASCO 2017; Abstr. 5520

Markman M., Bundy B., Alberts D., Fowler J., Clark–Pearson D., Carson L., Wadler S., Sickel J.: Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001

Mirza M.R., Monk B.J., Herrstedt J., Oza A.M., Mahner S., Redondo A., Fabbro M., Ledermann J.A., Lorusso D., Vergote I., Ben‑Baruch N.E., Marth C., Mądry R., Christensen R.D., Berek J.S., Rum A. D., Tinker A.V., du Bois A., González‑Martín A., Follana P., Benigno B., Rosenberg P., Gilbert L., Rimel B.J., Buscema J., Balser J.P., Agarwal S., Matulonis U.A., for the ENGOT-OV16/NOVA Investigators: Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. New Engl J Med 2016; 375: 2154–64

Mogensen O.: Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44: 207

Monk B.J, Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F.M., Pujade-Lauraine E., Lisyanskaya A.S., Makhson A.N., Rolski J., Gorbounova V.A., Ghatage P., Bidzinski M., Shen K., Ngan H.Y., Vergote I.B., Nam J.H., Park Y.C., Lebedinsky C.A., Poveda A.M.: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010 Jul 1; 28 (19): 3107

Moore K., Colombo N., Scambia C., Kim B.G., Oaknin A., Friedlander M., Lisyanskaya A., Floquet A., Leary A., Sonke G.S., Gourley Ch., Banjeree S., Oza A., Gonzalez-Martin A., Aghajanian C., Bradley W., Lowe E.S., Bloomfield R., Di Silvestro P.: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018 Oct 21; doi: 10.1056/NEJMoa1810858

Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C.O., Bast R.C. Jr.: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008c; 108 (2): 402–408

Moore R.G., Jabre-Raughley M., Brown A.K. et al.: Comparison of a novel multiple marker assay vs. the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228

Moore R.G., McMeekin D.S., Brown A.K. et al.: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40

Oza A.M., Cibula D., Benzaquen A.O., Poole C., Mathijssen R.H., Sonke G.S., Colombo N., Špaček J., Vuylsteke P., Hirte H., Mahner S., Plante M., Schmalfeldt B., Mackay H., Rowbottom J., Lowe E.S., Dougherty B., Barrett J.C., Friedlander M.: Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16 (1): 87

Pecorelli S., Odicino F., Maisonneuve P. et al.: Carcinoma of the ovary. Annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat 1998; 3: 75–102

Pfisterer J., Dean A.P., Baumann K., Rau J., Harter P., Joly F., Sehouli J., Canzler U., Schmalfeldt B., Shannon C., Hein A., Reimer D.U., Hanker L.C., Petit T., Marmé F., El-Balat A., Glasspool R., de Gregorio N., Mahner S., Kurtz J.-E.: Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. A prospective randomized Phase III ENGOT/ GCIG-Intergroup Study (AGO Study Group, AGO-Austria, ANZGOG, GINECO, SGCTG) AGO-OVAR 2.21/ENGOT-ov 18 NCT 01837251. ESMO 2018

Pignata S., Lorusso D., Joly F., Gallo C., Colombo N., Sessa C., Bamias A., Pisano C., Selle F., Zaccarelli E., Scambia G., Pautier P., Nicoletto M.O., De Giorgi U., Dubot C., Bologna A., Orditura M., Ray-Coquard I.L., Perrone F., Daniele G.: Chemotherapy plus or minus bevacizumab for platinum- sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16BMaNGO OV2B-ENGOT OV17. Proc ASCO 2018; Abstr. 5506

Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., Sorio R., Vergote I., Witteveen P., Bamias A., Pereira D., Wimberger P., Oaknin A., Mirza M.R, Follana P., Bollag D., Ray-Coquard I.: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32 (13): 1302–8

Pujade-Lauraine E., Ledermann J.A., Selle F., Gebski V., Penson R.T., Oza A.M., Korach J., Huzarski T., Poveda A., Pignata S., Friedlander M., Colombo N., Harter P., Fujiwara K., Ray-Coquard I., Banerjee S., Liu J., Lowe E.S., Bloomfield R., Pautier P., the SOLO2/ENGOT-Ov21 investigators 2017 SOLO 2: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 1274–84

Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., Gebski V., Heywood M., Vasey P.A., Volgger B., Vergote I., Pignata S., Ferrero A., Sehouli J., Lortholary A., Kristensen G., Jackisch C., Joly F., Brown C., Le Fur N., du Bois A.: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323–3329

Runnebaum I.B., Stickeler E.: Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001 Feb; 127 (2): 73–9

Rustin, G.J. et al.: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376 (9747): 1155–63

Scarabelli C., Gallo A., Franceschi S., Campagnutta E., De Piero G., Giorda G., Visentin M.C., Carbone A.: Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 2000; 88: 389–397

Shah C.A., Lowe K.A., Paley P. et al.: Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009; 18: 1365–72

Silverberg S.G.: Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol 1989; 78: 85–109

Statistik Austria, Österreichisches Krebsregister (Stand 2. 10. 2015)

Swisher E.M. et al.: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017 Jan; 18 (1): 75–8;. doi: 10.1016/S1470- 2045(16)30559-9

Thigpen T., Brady M.F., Omura G.A., Creasman W.T., McGuire W.P., Hoskins W.J., Williams S.: Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993; 71: 606–614

Timmerman D., Ameye L., Fischerova D., Epstein E., Melis G.B., Guerriero S., Van Holsbeke C., Savelli L., Fruscio R., Lissoni A.A., Testa A.C., Veldman J., Vergote I., Van Huffel S., Bourne T., Valentin L.: Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ 2010; 341

Trimble E.L., Kosary C.A., Cornelison T.L. et al.: Improved survival for women with ovarian cancer [Abstract]. In: Proceedings of the Society for Gynecologic Oncology 1999; Abstract 136

van de Laar R., Massuger L.F., Van Gorp T., IntHout J., Zusterzeel P.L., Kruitwagen R.F.: External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. Gynecol Oncol 2015; 137 (2): 210–5

van Driel W.J., Koole S.N., Sikorska K., Schagen van Leeuwen J.H., Schreuder H.W.R., Hermans R.H.M., de Hingh I.H.J.T., van der Velden J., Arts H.J., Massuger L.F.A.G., Aalbers A.G.J., Verwaal V.J., Kieffer J.M., Van de Vijver K.K., van Tinteren H., Aaronson N.K., Sonke G.S.: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med 2018; 378: 230–40

Vaughan S., Coward J.I., Bast R.C. Jr. et al.: Rethinking Ovarian Cancer: Recommendations for Improving Outcomes. Nat Rev Cancer 2011; 11 (10): 719–725

Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H., van der Burg M.E., Lacave A.J., Panici P.B., Kenter G.G., Casado A., Mendiola C., Coens C., Verleye L., Stuart G.C., Pecorelli S., Reed N.S.: European Organization for Research and Treatment of Cancer – Gynaecological Cancer Group; NCIC Clinical Trials Group: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363 (10): 943–53

Walker J.L., Brady M.F., DiSilvestro P.A., Fujiwara K., Alberts D., Zheng K.,Tewari K., Cohn D.E., Powell M., Van Le L., Rubin S., Davidson S.A., Gray H.j., Waggoner S., Myers T., Aghajanian C., Secord A.A., Mannel R.S.: A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology study. SGO 2016, Abstract 6

Walsh C.S.: Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecologic Oncoogy 2015; 137 (2): 343–350

Yancik R.: Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality [Review]. Cancer 1993; 71 (2 Suppl.): 517–523